Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Aquestive Therapeutics Inc | 24 |
| 2 | The University of Texas System | 19 |
| 3 | University of Alabama at Birmingham | 10 |
| 4 | The University of Texas at Austin | 9 |
| 5 | American Regent Inc | 8 |
| 6 | Eli Lilly and Co | 6 |
| 7 | Ascendis Pharma AS | 5 |
| 8 | Scripps Research Institute | 5 |
| 9 | University of Alabama | 5 |
| 10 | Celanese EVA Performance Polymers Inc | 4 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 120 |
| 2 | A61P | Therapeutic activity (drug indications) | 76 |
| 3 | A61M | Devices for introducing media into the body | 27 |
| 4 | C07D | Heterocyclic compounds | 17 |
| 5 | Y02A | Climate change adaptation | 16 |
| 6 | Y10T | Cross-reference (technical subjects) | 15 |
| 7 | A01N | Preservation of bodies; biocides; pest repellents | 14 |
| 8 | C08L | Polymer compositions (blends) | 14 |
| 9 | B81B | 11 | |
| 10 | B81C | 11 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Cancer Treatment and Pharmacology | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Charles R. Ashby | Stony Brook University | 2 |
| 2 | Marlene L. Cohen | Eli Lilly (United States) | 4 |
| 3 | J. S. Gidda | Eli Lilly (United States) | 3 |
| 4 | Rex Y. Wang | Stony Brook University | 2 |
| 5 | A.M. Bendele | Eli Lilly (United States) | 2 |
| 6 | Barbara J. Ring | Eli Lilly (United States) | 2 |
| 7 | C. John Parli | Eli Lilly (United States) | 2 |
| 8 | David W. Robertson | Eli Lilly (United States) | 2 |
| 9 | NULL AUTHOR_ID | 2 | |
| 10 | Steven Wrighton | Eli Lilly (United States) | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| The human drug metabolizing cytochromes P450 | 1996 | 166 | Pharmacogenetics and Drug Metabolism |
| Serotonergic modulation of cat bladder function before and after spinal transection | 1995 | 40 | Pain Mechanisms and Treatments |
| LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity. | 1990 | 40 | Gastrointestinal motility and disorders |
| The effect of acute and chronic LY 277359, a selective 5-HT3 receptor antagonist, on the number of spontaneously active midbrain dopamine neurons | 1991 | 32 | Schizophrenia research and treatment |
| In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A. | 1994 | 25 | Insect Pheromone Research and Control |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of zatosetron maleate?
Which organizations hold the most patents related to zatosetron maleate?
What are the primary research topics covered in zatosetron maleate publications?
How many patents and papers exist in the current database for zatosetron maleate?
What intellectual property classifications are most common for zatosetron maleate patents?